EUVIMEDOpdag EUVIMED
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen access · CC BY-NC 4.0

Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension

Christopher L Bowlus iD, Frederik Nevens, Kris V Kowdley, Alan Bonder iD, Thomas Capozza, Jing Li, Radhika Nair, Michael Trauner, David E Jones

Alimentary Pharmacology & Therapeutics · 2026-10 · 64 (8) · 1083-1096

DOI: 10.1111/apt.70832 ↗

At a glance

Klinische Studie (Phase III) in Alimentary Pharmacology & Therapeutics, published online on 2026-07-14. Written by Christopher L Bowlus and 8 co-authors. Institution: Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA. Major MEDLINE topics: Chenodeoxycholic Acid, Cholagogues and Choleretics, Liver Cirrhosis, Biliary. Cited 2 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Obeticholic acid (OCA) has been evaluated in patients with primary biliary cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA) in the 12‐month, double‐blind, phase 3 POISE trial. A 3‐year interim analysis of the open‐label extension (OLE) demonstrated a favourable safety profile with sustained improvements in liver biochemistries.

Aim

To present the final long‐term safety and efficacy data from the 5‐year POISE OLE.

Methods

All patients who entered the OLE ( N = 193) were started on OCA 5 mg daily for a minimum of 3 months, after which the dose could be increased. Safety and efficacy were evaluated in the overall OLE population. Additional analyses censored data points following OCA titration > 10 mg to align with the prescribing label.

Results

POISE was terminated after it was determined that the OLE had achieved its study objectives of sustained efficacy with no unexpected safety findings. With censoring of data points following OCA titration to > 10 mg, the most common treatment‐emergent adverse event (TEAE) was pruritus (70%); serious hepatic‐related TEAEs were reported in five patients (3%). The serious hepatic‐related TEAEs and deaths ( n = 2, 1%) were assessed by the Investigators as unrelated to OCA. Liver biochemistries improved throughout the OLE; the response rate for the POISE primary endpoint was 63% at Month 72. Liver stiffness, as measured by transient elastography, was stable over the study duration.

Conclusions

Findings from the POISE OLE support the safety and efficacy profile of long‐term OCA treatment for patients with PBC with inadequate response or intolerance to UDCA (NCT01473524). Trial Registration Phase 3 study of obeticholic acid in patients with primary biliary cirrhosis (POISE) ClinicalTrials.gov identifier: NCT01473524

Subjects

MeSH terms (MEDLINE)

Chenodeoxycholic AcidCholagogues and CholereticsLiver Cirrhosis, BiliaryAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodTreatment OutcomeUrsodeoxycholic Acid

Author keywords

alkaline phosphatasefibrosis stabilisationliver diseaseopen‐label extensionsafety‐related outcomes

Substances

Chenodeoxycholic AcidCholagogues and Cholereticsobeticholic acidUrsodeoxycholic Acid

Authors and institutions

  • Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA.
  • Department of Gastroenterology and Hepatology, University Hospital KU Leuven, Leuven, Belgium.
  • Liver Institute Northwest and Elon S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA.
  • Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Intercept Pharmaceuticals Inc., Morristown, New Jersey, USA.
  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

ORCID profiles: Christopher L Bowlus, Alan Bonder

Funding

  • Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A.

Cite

APA

Bowlus, C. L., Nevens, F., Kowdley, K. V., Bonder, A., Capozza, T., Li, J., Nair, R., Trauner, M., & Jones, D. E. (2026). Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension. Alimentary Pharmacology & Therapeutics, 64(8), 1083-1096. https://doi.org/10.1111/apt.70832

Vancouver

Bowlus CL, Nevens F, Kowdley KV, Bonder A, Capozza T, Li J, et al. Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension. Alimentary Pharmacology & Therapeutics. 2026;64(8):1083-1096. doi:10.1111/apt.70832

BibTeX
@article{Bowlus2026,
  author = {Bowlus, Christopher L and Nevens, Frederik and Kowdley, Kris V and Bonder, Alan and Capozza, Thomas and Li, Jing and Nair, Radhika and Trauner, Michael and Jones, David E},
  title = {Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {8},
  pages = {1083--1096},
  doi = {10.1111/apt.70832}
}
Start for free →